8,427 Shares in Abbott Laboratories $ABT Purchased by J.Safra Asset Management Corp

J.Safra Asset Management Corp bought a new stake in Abbott Laboratories (NYSE:ABT) in the 4th quarter, according to its most recent disclosure with the SEC. The fund bought 8,427 shares of the healthcare product maker’s stock, valued at approximately $1,056,000.

Several other hedge funds have also made changes to their positions in the business. Freemont Management S.A. increased its stake in shares of Abbott Laboratories by 197.2% during the 4th quarter. Freemont Management S.A. now owns 10,700 shares of the healthcare product maker’s stock worth $1,341,000 after purchasing an additional 7,100 shares in the last quarter. PFA Pension Forsikringsaktieselskab acquired a new stake in shares of Abbott Laboratories during the 4th quarter worth about $116,580,000. Thrivent Financial for Lutherans grew its holdings in shares of Abbott Laboratories by 24.3% during the fourth quarter. Thrivent Financial for Lutherans now owns 246,586 shares of the healthcare product maker’s stock worth $30,931,000 after buying an additional 48,286 shares in the last quarter. Danica Pension Livsforsikringsaktieselskab acquired a new position in shares of Abbott Laboratories in the third quarter valued at approximately $185,640,000. Finally, Net Worth Advisory Group acquired a new stake in Abbott Laboratories during the fourth quarter worth approximately $1,366,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Analyst Upgrades and Downgrades

ABT has been the topic of several analyst reports. Barclays decreased their price objective on Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating on the stock in a report on Monday, April 20th. Stifel Nicolaus lowered their price target on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a report on Friday, April 17th. Oppenheimer cut their price objective on shares of Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. Leerink Partners cut their price target on shares of Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating on the stock in a research note on Tuesday, April 21st. Finally, Evercore decreased their price target on shares of Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, Abbott Laboratories presently has an average rating of “Moderate Buy” and a consensus price target of $119.09.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott continues to gain attention for its cancer diagnostics growth story, with the Exact Sciences acquisition expanding its diagnostics portfolio and supportive screening data improving the long-term outlook. Mounting Evidence Backs Abbott’s Cancer Diagnostics Growth Story
• Positive Sentiment: Abbott also received a boost from news that it secured CE Mark for its Libre Duo dual glucose-ketone sensing technology, a potential growth driver in diabetes care. Abbott (ABT) Secures CE Mark for World’s First Dual Glucose-Ketone Sensing Technology for Diabetes
• Neutral Sentiment: ABT is being highlighted as a trending stock across financial media, suggesting rising investor interest but not necessarily a clear catalyst by itself. Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
• Neutral Sentiment: Analyst commentary also noted Abbott as a blue-chip, defensive name for long-term portfolios, reinforcing its stability and dividend appeal rather than signaling a near-term earnings surprise. New Investors: 3 Rock-Solid Stocks to Build Your Portfolio Around
• Negative Sentiment: Despite the positive business updates, the stock has still been trading lower, reflecting broader selling pressure and investor caution after recent gains. Abbott (ABT) Dips More Than Broader Market: What You Should Know

Abbott Laboratories Price Performance

ABT opened at $89.15 on Thursday. The company has a fifty day simple moving average of $92.01 and a 200 day simple moving average of $108.39. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. The firm has a market cap of $155.29 billion, a price-to-earnings ratio of 24.97, a PEG ratio of 1.52 and a beta of 0.63. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $139.06.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The business had revenue of $11.16 billion for the quarter, compared to analyst estimates of $10.99 billion. During the same period in the previous year, the company earned $1.09 earnings per share. The company’s revenue for the quarter was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Equities research analysts expect that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Daniel J. Starks acquired 10,000 shares of the firm’s stock in a transaction on Monday, April 27th. The stock was bought at an average cost of $92.65 per share, with a total value of $926,500.00. Following the acquisition, the director directly owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. The trade was a 0.15% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Philip P. Boudreau purchased 2,200 shares of Abbott Laboratories stock in a transaction dated Thursday, April 23rd. The shares were bought at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the transaction, the chief financial officer directly owned 2,200 shares of the company’s stock, valued at approximately $201,300. The trade was a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Corporate insiders own 0.46% of the company’s stock.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.